Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 94

Showing 26-50 of 94 citing articles:

Optical tools for visualizing and controlling human GLP-1 receptor activation with high spatiotemporal resolution
Loïc Duffet, Elyse T. Williams, Andrea Gresch, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 15
Cerebral glucagon‐like peptide‐1 receptor activation alleviates traumatic brain injury by glymphatic system regulation in mice
Chuanxiang Lv, Shuai Han, Zhuang Sha, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 29, Iss. 12, pp. 3876-3888
Open Access | Times Cited: 15
Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease
Cameron Noah Keighron, Sahar Avazzadeh, Katarzyna Goljanek‐Whysall, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 728-728
Open Access | Times Cited: 14
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Lidan Hu, Wenmin Wang, Xiangjun Chen, et al.
Brain‐X (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 5
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype
Toshihiro Noguchi, Hiroyuki Katoh, Satoshi Nomura, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 4
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials
Jihan K. Zaki, Jakub Tomasik, Sabine Bahn
Pharmacological Research (2025), pp. 107633-107633
Open Access
The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis
Daniel Toker, Jeffrey N. Chiang, Paul Vespa, et al.
Neurocritical Care (2025)
Open Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
Evaluating the Molecular Interactions between Type 2 Diabetes Mellitus and Parkinson’s Disease: Role of Antidiabetic Drugs as Promising Therapeutics
Irum Waheed, Talal Sikandri, Sumbal Zaheen, et al.
ACS Chemical Neuroscience (2025)
Closed Access
A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 × FAD mice by modulating mitophagy via the PINK1/Parkin pathway
Rongcong Luo, Yonghai Kang, He Ma, et al.
International Immunopharmacology (2025) Vol. 154, pp. 114612-114612
Closed Access
Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer’s Disease and Type 2 Diabetes
María José Carranza-Naval, Ángel del Marco, Carmen Hierro‐Bujalance, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 31
Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities
Mohammad Amin Manavi
Neuropeptides (2022) Vol. 94, pp. 102250-102250
Closed Access | Times Cited: 21
The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion
Mehmet Burak Yalçın, Ejder Saylav Bora, Oytun Erbaş
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 1, pp. 327-339
Open Access | Times Cited: 4
GLP-1(7–36) protected against oxidative damage and neuronal apoptosis in the hippocampal CA region after traumatic brain injury by regulating ERK5/CREB
Shuwei Wang, Aijun Liu, Chaopeng Xu, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Open Access | Times Cited: 4
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung‐Tai Kuo, et al.
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 4
Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials
Bixin Deng, Tiechao Ruan, Wenting Lu, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 15-27
Closed Access | Times Cited: 4
Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease
Aanchal Verma, Ahsas Goyal
European Journal of Pharmacology (2024) Vol. 982, pp. 176936-176936
Closed Access | Times Cited: 4
Antin-diabetic cognitive dysfunction effects and underpinning mechanisms of phytogenic bioactive peptides: a review
Xiaoli Liu, Sailu Mao, Yuxue Yuan, et al.
Frontiers in Nutrition (2025) Vol. 11
Open Access
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 1, pp. 105-123
Closed Access | Times Cited: 25
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Zijun Ma, Kaiqin Jin, Mengmeng Yue, et al.
Journal of Diabetes Research (2023) Vol. 2023, pp. 1-8
Open Access | Times Cited: 10
Qingxin Kaiqiao Fang decreases Tau hyperphosphorylation in Alzheimer's disease via the PI3K/Akt/GSK3β pathway in vitro and in vivo
Shuo Liu, Luting Xu, Yan Shen, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 117031-117031
Open Access | Times Cited: 9
GIP attenuates neuronal oxidative stress by regulating glucose uptake in spinal cord injury of rat
Beibei Guo, Mengwei Qi, Xiaoqian Luo, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 6
Open Access | Times Cited: 3
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
Suzanne M. de la Monte
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S317-S343
Closed Access | Times Cited: 3
Gut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1
Richard A. Manfready, Christopher B. Forsyth, Robin M. Voigt, et al.
Current Neurology and Neuroscience Reports (2022) Vol. 22, Iss. 7, pp. 335-342
Closed Access | Times Cited: 14
Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies
Kazunori Sango, Shizuka Takaku, Masami Tsukamoto, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 14

Scroll to top